Forschung
Wenn Sie ein Forschungsprojekt in Zusammenarbeit mit SSCS durchführen möchten, wenden Sie sich bitte an eines der unter «Wer sind wir» genannten Studienzentren.
Publikationen
Mihailovic J, Ribi C, Chizzolini C, Trendelenburg M, Von Kempis J, Dahdal S, Huynh-Do U; Swiss Systemic Lupus Erythematosus Cohort Study Group (SSCS).
Worse cardiovascular and renal outcome in male SLE patients.
Sci Rep. 2023 Oct 30;13(1):18628. doi:
10.1038/s41598-023-45171-7.
Horisberger A, Humbel M, Fluder N, Bellanger F, Fenwick C, Ribi C, Comte D.
Measurement of circulating CD21-CD27- B lymphocytes in SLE patients is associated with disease activity independently of conventional serological biomarkers. Sci Rep. 2022 Jun 2;12(1):9189. doi: 10.1038/s41598-022-12775-4. PMID: 35654865.
Humbel M, Bellanger F, Horisberger A, Suffiotti M, Fluder N, Makhmutova M, Mathias A, Du Pasquier R, Fenwick C, Ribi C, Comte D.
SLAMF Receptor Expression Identifies an Immune Signature That Characterizes Systemic Lupus Erythematosus.
Front Immunol. 2022 May 6;13:843059. doi: 10.3389/fimmu.2022.843059. PMID: 35603218; PMCID: PMC9120573.
Breillat P, Jachiet M, Ditchi Y, Lenormand C, Costedoat-Chalumeau N, Mathian A, Moguelet P, Duriez P, Trendelenburg M, Huynh-Do U, Chizzolini C, Beuvon C, Roy-Peaud F, Bouaziz JD, Barbaud A, Francès C, Mékinian A, Fain O, Amoura Z, Chasset F; for EMSED study group (Etude des maladies systémiques en dermatologie) and the Swiss SLE Cohort Study (SSCS).
Cutaneous vasculitis occurring in the setting of systemic lupus erythematosus: a multicentre cohort study.
Rheumatology (Oxford). 2023Jun 1;62(6):2189-2196. doi: 10.1093/rheumatology/keac566.
Neziraj T, Siewert L, Pössnecker E, Pröbstel AG.
Therapeutic targeting of gut-originating regulatory B cells in neuroinflammatory diseases.
Eur J Immunol. 2023 Nov;53(11):e2250033. doi: 10.1002/eji.202250033.
Gualtierotti R, Meroni PL, Beltagy A, El-Girby A, Emmi G, Chizzolini C, Migliorini P, Bossuyt X, Pregnolato F, Rönnelid J, Borghi MO, Moroni G.
Are IF-ANA the guiding light for SLE classification in the real-world setting?
Autoimmun Rev. 2022 Sep;21(9):103138. doi: 10.1016/j.autrev.2022.103138. Epub 2022 Jul 6. PMID: 35809881
Chasset F, Mathian A, Dorgham K, Ribi C, Trendelenburg M, Huynh-Do U, Roux-Lombard P, Courvoisier DS, Amoura Z, Gorochov G, Chizzolini C for the Swiss SLE Cohort Study (SSCS).
Serum Interferon-α levels and IFN type I-stimulated genes score perform equally to assess systemic lupus erythematosus disease activity. Ann Rheum Dis 2022 (in press).
Kleer JS et al.
Epitope-Specific Anti-C1q Autoantibodies in Systemic Lupus Erythematosus. Front Immunol 2022 (in press).
Clottu AS, Humbel M, Fluder N, Karampetsou MP, Comte D.
Innate Lymphoid Cells in Autoimmune Diseases. Front Immunol. 2022 Jan 7;12:789788. doi.org: 10.3389/fimmu.2021.789788
Clottu A, Horisberger A, Comte D.
Biologiques et lupus érythémateux systémique : nouveautés et perspectives [Biologics and systemic lupus erythematosous : new insights and perspectives]. Rev Med Suisse. 2021 Apr 7;17(733):684-689. French. PMID: 33830700.
Humbel M, Bellanger F, Fluder N, Horisberger A, Suffiotti M, Fenwick C, Ribi C, Comte D.
Restoration of NK Cell Cytotoxic Function With Elotuzumab and Daratumumab Promotes Elimination of Circulating Plasma Cells in Patients With SLE. Front Immunol. 2021 Mar 22;12:645478. doi: 10.3389/fimmu.2021.645478. PMID: 33828555; PMCID: PMC8019934.
Collins CE, Cortes-Hernández J, Garcia MA, von Kempis J, Schwarting A, Touma Z, Kurtinecz M, Gairy K.
Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies. Rheumatol Ther. 2020 Dec;7(4):949-965. doi: 10.1007/s40744-020-00243-2.
Kiener S, Ribi C, Keller I, Chizzolini C, Trendelenburg M, Huynh-Do U, von Kempis J, on behalf of Swiss SLE Cohort Study SSCS, Leeb T.
Variants Affecting the C-Terminal Tail of UNC93B1 Are Not a Common Risk Factor for Systemic Lupus Erythematosus. Genes (Basel). 2021 Aug 19;12(8):1268. doi: 10.3390/genes12081268.
Chasset F, Dayer JM, Chizzolini C.
Type I Interferons in Systemic Autoimmune Diseases: Distinguishing Between Afferent and Efferent Functions for Precision Medicine and Individualized Treatment. Front Pharmacol. 2021 Apr 14;12:633821. doi: 10.3389/fphar.2021.633821.
Chasset F, Ribi C, Trendelenburg M, Huynh-Do U, Roux-Lombard P, Courvoisier DS, Chizzolini C on behalf of the Swiss SLE Cohort Study (SSCS).
Identification of highly active systemic lupus erythematosus patients through combined type-I interferon and neutrophil gene scores compared to classical serological markers. Rheumatology (Oxford) 2020; keaa167. doi:10.1093/rheumatology/keaa167.
Kieninger-Gräfitsch A, Vogt S, Ribi C, Dubler D, Chizzolini C, Huynh-Do U, Osthoff M, Trendelenburg M.
No association of functional deficiency of complement mannose-binding lectin with cardiovascular disease in patients with Systemic Lupus Erythematosus. Sci Rep 2020; 10: 3693. doi: 10.1038/s41598-020-60523-3.
Nigolian H, Ribi C, Courvoisier D, Pagano S., Alvarez M, Trendelenburg M, Huyuh-Do U, Vuilleumier N, Dayer J-M, Chizzolini C, Roux-Lombard P.
Anti-apolipoprotein A1 autoantibodies correlate with disease activity markers in SLE. Rheumatology (Oxford). 2020; 59: 534-544. doi: 10.1093/rheumatology/kez306.
Friebus-Kardash J, Trendelenburg M, Eisenberger U, Ribi C, Chizzolini C, Huynh-Do U, Lang KS, Wilde B, Kribben A, Witzke O, Dolff S, Hardt C.
Susceptibility of BAFF-var allele carriers to severe SLE with occurrence of lupus nephritis. BMC Nephrol 2019; 20: 430. doi: 10.1186/s12882-019-1623-4.
Csorba K, Schirmbeck LA, Tuncer E, Ribi C, Roux-Lombard P, Chizzolini C, Huynh-Do U, Vanhecke D, Trendelenburg M. Anti-C1q antibodies as occurring in systemic lupus erythematosus could be induced by an Epstein-Barr virus-derived antigenic site. Front Immunol 2019; 10: 2619. doi: 10.3389/fimmu.2019.02619.
Troldborg A, Steffensen R, Trendelenburg M, Hauser T, Winther KG, Hansen AG, Stengaard-Pedersen K, Voss A, Thiel S.
Ficolin-3 deficiency is associated with disease and an increased risk of Systemic Lupus Erythematosus. J Clin Immunol 2019; 39: 421-429.
Nehring J, Schirmbeck LA, Friebus-Kardash J, Dubler D, Huynh-Do U, Chizzolini C, Ribi C, Trendelenburg M. Autoantibodies Against Albumin in Patients With Systemic Lupus Erythematosus. Front Immunol. 2018 Oct 2;9:2090. doi: 10.3389/fimmu.2018.02090. eCollection 2018.
Pröbstel AK, Thanei M, Erni B, Lecourt AC, Branco L, André R, Roux-Lombard P, Koenig KF, Huynh-Do U, Ribi C, Chizzolini C, Kappos L, Trendelenburg M, DerfussT.
Association of antibodies against myelin and neuronal antigens with neuroinflammation in systemic lupus erythematosus. Rheumatology (Oxford). 2018 Sep 27. doi:
10.1093/rheumatology/key282. [Epub ahead of print]
Troldborg A, Thiel S, Trendelenburg M, Friebus-Kardash J, Nehring J, Steffensen R, Hansen SW, Laska MJ, Deleuran B, Jensenius JC, Voss A, Stengaard-Pedersen K. Lectin
Pathway Proteins in Patients with Systemic Lupus Erythematosus And Association with Complement Activation and Disease Activity. J Rheumatol. 2018 Aug;45(8):1136-1144.
Marchetti T, Ribi C, Perneger T, Trendelenburg M, Huynh-Do U, de Moerloose Ph, Chizzolini C.
Prevalence, persistence, and clinical correlations of classic and novel antiphospholipid antibodies in systemic lupus erythematosus. Rheumatology (Oxford). 2018 Aug 1;57(8):1350-1357.
Dahdal S, Devetzis V, Chalikias G, Tsiakas D, Chizzolini C, Ribi C, Trendelenburg M, Eisenberger U, Hauser T, Pasch A, Huynh-Do U, Arampatzis S.
Serum Calcification Propensity for Assessment of disease activity in Systemic Lupus Erythematosus. PLoS One 2018 Jan 24;13(1):e0188695.
Chaigne B, Chizzolini C, Perneger T, Trendelenburg M, Huynh-Do U, Dayer E, Stoll T, von Kempis J, Ribi C.
Impact of disease activity on health-related quality of life in systemic lupus erythematosus - a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS). BMC Immunol. 2017; 18: 17. doi: 10.1186/s12865-017-0200-5.
Friebus-Kardash J, Branco L, Ribi C, Chizzolini C, Huynh-Do U, Dubler D, Roux-Lombard P, Dolff S, Kribben A, Eisenberger U, Trendelenburg M.
Immune complexes containing serum B-cell activating factor and immunoglobulin G correlate with disease activity in systemic lupus erythematosus. Nephrol Dial Transplant. 2017 Aug 8. doi: 10.1093/ndt/gfx220. [Epub ahead of print]
Chaigne B, Finckh A, Alpizar- Rodriguez D, Courvoisier D, Ribi C, Chizzolini C,
For The Swiss Clinical Quality Management Program For Rheumatoid Arthritis and The Swiss Systemic Lupus Erythematosus Cohort Study Group. Differential impact of systemic lupus erythematosus and rheumatoid arthritis on health-related quality of life. Qual Life Res 2017; 26: 1767–1775.
Trendelenburg M, Ribi C.
The Swiss SLE Cohort Study (SSCS). Rheuma-Schweiz 2016; 1: 7-10.
Koenig K, Ribi C, Radosavac, M, Zulewsky H, Trendelenburg M.
Prevalence of vascular disease in SLE compared to type-1 diabetes mellitus: a cross-sectional study of two cohorts. Lupus 2015; 24: 58-65.
Ribi C, Trendelenburg M, Gayet-Ageron A, Cohen CD, Dayer E, Eisenberger U, Hauser T, Hunziker T, Leimgruber A, Lindner G, König KF, Otto P, Spertini F, Stoll T, von Kempis J, Chizzolini C for the Swiss SLE cohort study (SSCS).
The Swiss Systemic lupus erythematosus Cohort Study (SSCS) – I – Cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland. Swiss Med Weekly 2014; 144: w13990.
Trendelenburg M, Ribi C für die Mitglieder der SSCS. Systemischer Lupus Erythematodes - die Swiss SLE Cohort Study (SSCS). Swiss Med Forum 2013; 13: 439-440.
Chizzolini C, Cohen CD, Eisenberger U, Hauser T, Hunziker T, Leimgruber A, Pechula M, Ribi C, Stoll T, Trendelenburg M.
Création d’une cohorte de patients lupique: the Swiss systemic lupus erythematosus cohort study (SSCS). Revue médicale suisse 2009; 199: 808-811.